Robert Barrow Sells 25,791 Shares of Mind Medicine (MindMed) (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CEO Robert Barrow sold 25,791 shares of Mind Medicine (MindMed) stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the transaction, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This represents a 3.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mind Medicine (MindMed) Stock Performance

Shares of Mind Medicine (MindMed) stock opened at $12.95 on Wednesday. The business has a 50-day moving average price of $12.34 and a two-hundred day moving average price of $10.51. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $14.43. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31. The company has a market cap of $1.28 billion, a P/E ratio of -6.35 and a beta of 2.57.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.26). As a group, analysts anticipate that Mind Medicine will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP boosted its holdings in Mind Medicine (MindMed) by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after acquiring an additional 828,067 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Mind Medicine (MindMed) by 16.2% in the first quarter. Wellington Management Group LLP now owns 225,928 shares of the company’s stock valued at $1,322,000 after purchasing an additional 31,437 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Mind Medicine (MindMed) by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after purchasing an additional 66,663 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in Mind Medicine (MindMed) by 18.1% during the first quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company’s stock worth $2,282,000 after purchasing an additional 59,868 shares during the last quarter. Finally, Persistent Asset Partners Ltd bought a new stake in Mind Medicine (MindMed) in the 2nd quarter worth about $238,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

More Mind Medicine (MindMed) News

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM‑120 moved into Phase III for GAD and MDD with pivotal readouts expected in 2026 — a clear near‑term clinical catalyst that supports upside expectations for the stock. Read More.
• Positive Sentiment: Broker and analyst enthusiasm (including recent buy/strong‑buy coverage and a handful of high targets) is lifting sentiment and provides potential support for the stock ahead of clinical readouts. Read More.
• Neutral Sentiment: Analyst/ownership mix is mixed: consensus ratings skew positive with an elevated average price target, while institutional ownership (~28%) gives market credibility but also means larger holders could add to volatility. Read More.
• Negative Sentiment: Clustered insider selling on Dec. 26 — CEO Robert Barrow (25,791 shares), Mark Sullivan (11,276 shares) and Daniel Karlin (5,600 shares) — has introduced immediate selling pressure and is the most direct reason cited for the stock trading down today. Read More.
• Negative Sentiment: Fundamental headwinds remain — recent quarterly results missed estimates and analysts model negative EPS for the year, which increases sensitivity to execution and clinical outcomes. Read More.

Analyst Ratings Changes

A number of research analysts recently issued reports on MNMD shares. Chardan Capital upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mind Medicine (MindMed) in a report on Wednesday, October 8th. Royal Bank Of Canada reduced their target price on Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, November 7th. Jones Trading initiated coverage on Mind Medicine (MindMed) in a research note on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price target on the stock. Finally, Canaccord Genuity Group raised their price objective on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $30.33.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.